Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 0.1× earnings vs its 0.4× historical median P/E.
Fair value ≈ $66.85 · price $15.98 today
Undervalued · 76% below
Loading valuation…
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Truist reiterated $NUVB Buy; $12
$DSNKY DSKYF $HCM BAYRY LLY RIGL
Here's what Truist said in its note: https://x.com/Quantumup1/status/2039382081814286759?s=20
Citizens🏁 $IMMP and said, We are initiating coverage of Immutep Limited with a Market Outperform rating and $6 price target based on a revenue and earnings multiple analysis.
$MRK AUTL ALLO ANL $SMMT $DSNKY - AZN BMY $NUVL
Here's what else Citizens had to say: https://x.com/Quantumup1/status/2023730370282197356?s=20
Nice work in 2025, $NUVB $JAZZ $AMGN $DSNKY (and others) 👍
🫁 but countless Lung cancer patients are still waiting ⏰
@BioCapitalist99 and @Biotech_Beast know
UBS reiterated $IDYA at Buy-$50-Top Pick and said, we believe $IDYA's lead asset, darovasertib (daro), is a transformative therapy for uveal melanoma, yet underappreciated by the market - we est a $1.3B peak sales potential while the Street is pricing in $800M peak at the current stock price.
We believe daro's impressive clinical efficacy, clean
safety, and convenient oral dosing could enable its use over the current standard of care in front-line and neoadjuvant uveal melanoma.
More importantly, we see several high conviction near-term catalysts over the next 6 months that could drive significant upside for the stock.
These include
1) daro Phase 2 readout in neoadjuvant enucleation cohort at ESMO medical conference (Oct 17-21),
2) daro Phase 2 overall survival data in 1L metastatic uveal melanoma at SMR medical conference (Oct 25-28), and
3) daro pivotal Phase 3 data in 1L metastatic uveal melanoma (HLA-A2-) in 4Q25-1Q26.
$GILD $SMMT $BNTX $DSNKY
